Bessemer Group
GLUE icon

Bessemer Group’s Monte Rosa Therapeutics GLUE Stock Holding History

Bessemer Group’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-34
Closed -$1K – 2581
2025
Q4 		$1K Hold
34
– – ﹤0.01% 2470
2025
Q3 		$0 Buy
+34
New +$180 ﹤0.01% 2574

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Bessemer Group's GLUE Position: Q1 2026 in Review

Bessemer Group sold out of Monte Rosa Therapeutics (GLUE) in Q1 2026, closing a stake of 34 shares — an estimated $1K sold.

Bessemer Group first reported a position in GLUE in Q3 2025 and held it in 2 quarters. The position peaked at $1K in Q4 2025. 191 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Bessemer Group reported no remaining Monte Rosa Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bessemer Group sold 34 Monte Rosa Therapeutics shares in Q1 2026, an estimated $1K.
  • Bessemer Group first reported a position in Monte Rosa Therapeutics in Q3 2025 and held it in 2 quarters.
  • Bessemer Group's Monte Rosa Therapeutics position peaked at $1K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.